Drug Profile
Research programme: chimeric antigen receptor-targeted therapies - Novartis/University of Pennsylvania
Alternative Names: Adoptive T-cell immunotherapies - University of Pennsylvania/Novartis; CAR immunotherapies - University of Pennsylvania/NovartisLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Novartis; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 13 Dec 2019 Preclinical development is ongoing in USA
- 13 Dec 2019 Oxford BioMedica extends commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products